Please upgrade your browser.
The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging.
The findings were presented Saturday during a special news conference at the American Urological Association (AUA) annual meeting in Washington, D.C. Research presented at meetings should be viewed as preliminary because it has not been subjected to the peer review that typically accompanies publication in a medical journal.
Dr. Marston Linehan gets animated talking about kidney cancer. You can see his passion for his work in every gesture.
The incidence of renal cell carcinoma (RCC) is increasing and outcomes remain poor. One-third of patients with localized disease will relapse, and 5-year survival for patients with metastatic disease is less than 10%.
Bill Bro, CEO, Kidney Cancer Association interviews Linda Cairns, Ph.D. Learn how ecancer.TV benefits patients and medical professionals alike. Recorded at the Sixth International European Kidney Cancer Symposium, Warsaw Poland.
Global kidney cancer charity sponsors contest to ID the top five bloggers. Finalists, selected in public voting, receive an iPod Shuffle and invitation to blog live from the International Kidney Cancer Symposium.
A suspected cluster of rare kidney cancers occurring in Marine City, Michigan, are being investigated by Michigan health officials following the diagnosis of a six-month-old girl in March. Over the last four years, five cases have been diagnosed in this town with a population of about 5,000. The rare kidney cancer called Wilms tumor typically strikes 500 Americans annually.
Patients who develop high blood pressure while being treated for advanced kidney cancer with the drug sunitinib respond better to treatment, maintain longer progression-free survival, and survive longer, according to a Cleveland Clinic-led study.
The trial will evaluate the efficacy and safety of Xcytrin used as a single agent in approximately 40 patients with metastatic renal cell carcinoma.
|Powered by NeonCRM|